

Louise B Russell

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8903896/publications.pdf>

Version: 2024-02-01

37
papers

2,929
citations

777949

13
h-index

445137

33
g-index

38
all docs

38
docs citations

38
times ranked

5519
citing authors

#	ARTICLE	IF	CITATIONS
1	The Electronic Health Record as the Primary Data Source in a Pragmatic Trial: A Case Study. <i>Medical Decision Making</i> , 2022, , 0272989X2110699.	1.2	1
2	Effects of non-pharmaceutical interventions on social distancing during the COVID-19 pandemic: Evidence from the 27 Brazilian states. <i>PLoS ONE</i> , 2022, 17, e0265346.	1.1	4
3	Remote Monitoring and Behavioral Economics in Managing Heart Failure in Patients Discharged From the Hospital. <i>JAMA Internal Medicine</i> , 2022, 182, 643.	2.6	14
4	Using Clinical Trial Data to Estimate the Costs of Behavioral Interventions for Potential Adopters: A Guide for Trialists. <i>Medical Decision Making</i> , 2021, 41, 9-20.	1.2	7
5	Comparison of static and dynamic models of maternal immunization to prevent infant pertussis in Brazil. <i>Vaccine</i> , 2021, 39, 158-166.	1.7	4
6	The data used to build the models: Pertussis morbidity and mortality burden considering various Brazilian data sources. <i>Vaccine</i> , 2021, 39, 137-146.	1.7	3
7	Electronic Health Records: The Signal and the Noise. <i>Medical Decision Making</i> , 2021, 41, 103-106.	1.2	5
8	Association of COVID-19 Outbreak with Changes in Physical Activity Among Adults with Elevated Risk for Major Adverse Cardiovascular Events. <i>Journal of General Internal Medicine</i> , 2021, 36, 3625-3628.	1.3	1
9	Qualitative Exploration of Barriers to Statin Adherence and Lipid Control. <i>JAMA Network Open</i> , 2021, 4, e219211.	2.8	4
10	Cost-Effectiveness of Four Financial Incentive Programs for Smoking Cessation. <i>Annals of the American Thoracic Society</i> , 2021, 18, 1997-2006.	1.5	3
11	Evaluating the cost-effectiveness of maternal pertussis immunization in low- and middle-income countries: A review of lessons learnt. <i>Vaccine</i> , 2021, 39, 121-124.	1.7	3
12	Cost-effectiveness of maternal pertussis immunization: Implications of a dynamic transmission model for low- and middle-income countries. <i>Vaccine</i> , 2021, 39, 147-157.	1.7	6
13	Modeling the cost-effectiveness of maternal acellular pertussis immunization (aP) in different socioeconomic settings: A dynamic transmission model of pertussis in three Brazilian states. <i>Vaccine</i> , 2021, 39, 125-136.	1.7	6
14	Effect of Financial Incentives for Process, Outcomes, or Both on Cholesterol Level Change. <i>JAMA Network Open</i> , 2021, 4, e2121908.	2.8	1
15	Effect of Patient Financial Incentives on Statin Adherence and Lipid Control. <i>JAMA Network Open</i> , 2020, 3, e2019429.	2.8	18
16	Estimating Transition Probabilities from Published Evidence: A Tutorial for Decision Modelers. <i>Pharmacoeconomics</i> , 2020, 38, 1153-1164.	1.7	31
17	The Habit Formation trial of behavioral economic interventions to improve statin use and reduce the risk of cardiovascular disease: Rationale, design and methodologies. <i>Clinical Trials</i> , 2019, 16, 399-409.	0.7	8
18	Rationale and Design of EMPOWER, a Pragmatic Randomized Trial of Automated Hovering in Patients With Congestive Heart Failure. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e005126.	0.9	11

#	ARTICLE	IF	CITATIONS
19	Using Cluster Analysis to Group Countries for Cost-effectiveness Analysis: An Application to Sub-Saharan Africa. <i>Medical Decision Making</i> , 2018, 38, 139-149.	1.2	7
20	Future Directions for Cost-effectiveness Analyses in Health and Medicine. <i>Medical Decision Making</i> , 2018, 38, 767-777.	1.2	58
21	Cost-effectiveness of a potential group B streptococcal vaccine for pregnant women in the United States. <i>Vaccine</i> , 2017, 35, 6238-6247.	1.7	29
22	Cost-effectiveness of maternal GBS immunization in low-income sub-Saharan Africa. <i>Vaccine</i> , 2017, 35, 6905-6914.	1.7	34
23	What Pertussis Mortality Rates Make Maternal Acellular Pertussis Immunization Cost-Effective in Low- and Middle-Income Countries? A Decision Analysis. <i>Clinical Infectious Diseases</i> , 2016, 63, S227-S235.	2.9	9
24	Blood Pressure Measurement Biases in Clinical Settings, Alabama, 2010â€“2011. <i>Preventing Chronic Disease</i> , 2016, 13, E01.	1.7	11
25	Using Cost-Effectiveness Analysis in Health and Medicine. , 2016, , 1-38.		6
26	Strengthening Cost-Effectiveness Analysis for Public Health Policy. <i>American Journal of Preventive Medicine</i> , 2016, 50, S6-S12.	1.6	17
27	Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 1093.	3.8	2,149
28	Recommendations on Perspectives for the Reference Case. , 2016, , 67-74.		4
29	Handling Parameter Uncertainty in Cost-Effectiveness Models Simply and Responsibly. <i>Medical Decision Making</i> , 2015, 35, 567-569.	1.2	5
30	Risk factors for family time burdens providing and arranging health care for children with special health care needs: Lessons from nonproportional odds models. <i>Social Science Research</i> , 2015, 52, 602-614.	1.1	15
31	Do We Really Value Identified Lives More Highly Than Statistical Lives?. <i>Medical Decision Making</i> , 2014, 34, 556-559.	1.2	10
32	Cost-effectiveness of a potential group B streptococcal vaccine program for pregnant women in South Africa. <i>Vaccine</i> , 2014, 32, 1954-1963.	1.7	53
33	Looking at Patientsâ€™ Choices through the Lens of Expected Utility. <i>Medical Decision Making</i> , 2012, 32, 527-531.	1.2	5
34	Conceptualizing a Model. <i>Medical Decision Making</i> , 2012, 32, 678-689.	1.2	216
35	Preventing Chronic Disease: An Important Investment, But Donâ€™t Count On Cost Savings. <i>Health Affairs</i> , 2009, 28, 42-45.	2.5	104
36	How Much Time Do Patients Spend on Outpatient Visits?. <i>Patient</i> , 2008, 1, 211-222.	1.1	35

#	ARTICLE	IF	CITATIONS
37	Health-Related Activities in the American Time Use Survey. <i>Medical Care</i> , 2007, 45, 680-685.	1.1	32